---
title: "KFSYSCC Fellowship Tuesday Morning Journal Club"
date: "2023-12-12 17:45:33"
enableToc: false
tags:
  - building
---

> [!info]
>
> üå±‰æÜËá™: [[alki in nsclc]]

# KFSYSCC Fellowship Tuesday Morning Journal Club

### 2023-12-12

# <!--fit-->**Treatment of <br>ALK Translocation-Positive<br>Non-Small Cell Lung Cancer**

### Siblings

- [[KFSYSCC Fellowship Tuesday Morning Journal Club]]
- [[ÊûóÂçîÈúÜ,<sup>1</sup>; Âê≥ËåÇÈùí<sup>2</sup>]]
- [[Patient 1: 58-year-old man]]
- [[Increasing number of FDA-approved drugs for treatment of oncogene-addicted NSCLC]]
- [[Anaplastic lymphoma kinase and ALK inhibitors]]
- [[Domain structure of receptor tyrosine kinase families]]
- [[Gene fusion between EML4 and ALK]]
- [[Signaling Pathways Activated by ALK Fusion Proteins]]
- [[Therapeutic Sequencing in ALK+ NSCLC]]
- [[<!--fit-->1st generation ALKi]]
- [[First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer]]
- [[Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer]]
- [[<!--fit-->2nd generation of ALKi]]
- [[Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer]]
- [[Alectinib vs crizotinib in ALK+ NSCLC (J-ALEX): <br>an open-label, randomised phase 3 trial]]
- [[Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA)]]
- [[OS]]
- [[Alectinib versus chemotherapy in crizotinib pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer]]
- [[Outcome]]
- [[<!--fit-->2nd generation ALKi]]
- [[Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer]]
- [[Survival without intracranial disease progression with brain metastasis at baseline]]
- [[Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib]]
- [[Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial]]
- [[<!--fit-->Yet another 2nd generation ALKi]]
- [[First-line **ceri**tinib versus platinum-based chemotherapy]]
- [[<!--fit-->3rd generation ALKi]]
- [[First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer]]
- [[Cumulative Incidence of CNS Progression as First Event]]
- [[Timeline in the development of the AEs of lorlatiib]]
- [[Compare Trials of ALKi]]
- [[Schematic total PFS comparison]]
- [[Mechanisms of resistance of ALKi]]
- [[Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer]]
- [[PFS by EML4-ALK v1 versus v3 detected by cDNA (CROWN, ALEX, ALTAl-1L)]]
- [[Secondary Mutations within EML4-ALK]]
- [[Characteristics of the pooled population of 450 ALK inhibitor resistant]]
- [[Clinical Benefit for ALK Resistance Mutations From Sequential ALK Inhibitors]]
- [[Take Home Message]]
- [[<!--fit-->_Have a nice day_]]
- [[Addendum]]
- [[ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer]]

